Bone Marrow Biopsy Report — Interpretation

Report Findings Summary (from the image)

• Bone marrow biopsy shows an overall cellularity of ~70% (hypercellular, age-adjusted)
• Trilineage proliferation with predominantly myeloid and megakaryocytic expansion
• Megakaryocytes are increased in number and show predominant erythroid morphology (atypia)
• Erythroid precursors are also noted
• Borderline lymphoid aggregates are also noted — no lymphoma pattern identified
• Stains and immunohistochemistry: no evidence of autonomy of blasts
• Features suggestive of Sjögren's syndrome, ANCA, or other autoimmune process
• Impression: Myeloproliferative Neoplasm (MPN), Grade 2–3 (Overt)
• Advice: Correlate ECF & CT; ICS is advisable — further BLOCKS provided with the report

Diagnosis

Primary Diagnosis:

• Age-adjusted hypercellularity (~70%)
• Trilineage proliferation with megakaryocytic atypia and proliferation
• Reticulin/collagen fibrosis Grade 2–3 (Overt)
• No significant blast increase

Differential Diagnoses

1. Primary Myelofibrosis (PMF) — Overt Phase (Most likely)

• Hypercellular marrow with megakaryocytic atypia + Grade 2–3 fibrosis fits PMF overt criteria exactly
• JAK2/CALR/MPL mutation testing required to confirm clonality
• Associated with splenomegaly, constitutional symptoms, and cytopenias

2. Post-Polycythemia Vera Myelofibrosis (Post-PV MF)

• PV can progress to a "spent phase" with marrow fibrosis indistinguishable histologically from PMF
• History of elevated hemoglobin/hematocrit, prior JAK2 V617F mutation, and erythroid predominance would support this
• The erythroid component noted on biopsy raises this possibility

3. Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

• ET with JAK2, CALR, or MPL mutation can evolve into fibrotic MPN
• Prominent megakaryocytic hyperplasia with atypia is shared feature
• Prior history of thrombocytosis would distinguish this from PMF

4. Reactive Myelofibrosis (Secondary)

• The borderline lymphoid aggregates and suggestion of Sjögren's syndrome / ANCA-associated autoimmune disease raise the possibility of reactive/secondary marrow fibrosis
• Causes include: autoimmune diseases (SLE, Sjögren's), infections (TB, HIV), lymphoma, and metastatic carcinoma
• Critical distinction: Reactive fibrosis lacks clonal driver mutations (JAK2/CALR/MPL negative)
• Autoimmune serologies (ANA, anti-Ro/La for Sjögren's, ANCA panel) must be correlated

5. Chronic Myeloid Leukemia (CML) with Fibrosis

• BCR::ABL1 must be excluded before diagnosing any classical MPN
• Generally shows granulocytic predominance without significant megakaryocytic atypia

6. Lymphoma with Bone Marrow Involvement

• Lymphoid aggregates are noted; however, the report states no lymphoma pattern
• Non-Hodgkin lymphoma (particularly low-grade B-cell, e.g. MZL, FL) can involve marrow
• Immunohistochemistry (CD20, CD3, CD10, BCL2) should be reviewed to exclude this

Recommended Workup

Summary: The biopsy is most consistent with an overt fibrotic myeloproliferative neoplasm, most likely Primary Myelofibrosis (PMF) Grade 2–3. The concurrent lymphoid aggregates and clinical context suggesting autoimmune disease (Sjögren's/ANCA) must be carefully excluded as causes of reactive myelofibrosis before committing to a primary MPN diagnosis. Molecular studies (JAK2/CALR/MPL, BCR::ABL1) and clinical correlation with CT imaging are imperative for definitive classification.